维普期刊资源整合服务平台（V6.5）

50篇 您的检索式：作者名="Laeis"

选中清除导出查看参考文献查看引证文献引用追踪共3页首页上一页第1页下一页末页 /3 跳转

	题名	作者	年代	出处	被引量
1	Intrafamilial phenotypic variability in families with RDS mutations: exclusion of ROM1 as a genetic modifier for those with retinitis pigmentosa显示文摘	Leroy BP Kailasanathan A de Laey JJ	2007	Br J Ophthalmol2007，91，1：	1
2	The interrelated roles of TGF- beta and IL-10 in the regulation of experimental colitis显示文摘	Fuss U Boirivant M Laey B	2002	J Immunol2002，168，2：	1
3	Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation显示文摘	Laey DL Timms E Tan HL	1998	Cell1998，93，2：	1
4	Olmesartan medoxornil:influence of age, renal and hepatic function on the pharmacokinetics of olmesartan medoxomil显示文摘	Bergmann K Laeis P Puchler K	2001	J Hypertens2001，19，1：	1
5	Clinical efficacy of olesartan medoxomil显示文摘	Brunner H R Laeis P T	2004	J Hypert2004，21，2：	1
6	Neovascularization after argon laser photocoagulation of macular lesions显示文摘	Francois J De Laey J J Cambie E	1975	Am J Ophthalmol1975，，：	1
7	The ocular ischemic syndrome显示文摘	Dhooge M de Laey JJ	1989	Bull Soc Belge Ophtalmol1989，231，：	1
8	Effects of fluticasone on systemie maskers of inflammation in chronic obstructive pulmonary disease 显示文摘	Sin DD Laey P York E	2004	Am J Respir Crit Care Med2004，170，7：	1
9	Differential Impact of Blood Pressure - Lowering Drags on Central Aortic Pressure and Clinical Outcomes: Prinelpal Results of the Conduit Artery Func- tion Evaluation (CAFE) Study 显示文摘	Williams B Laey PS Thom SM	2006	Circulation2006，113，9：	1
10	Electrophysiologic studies in birdshot chorioretinopathy显示文摘	De Rouck A De Laey JJ	1988	Am J Ophthalmol1988，106，：	1
11	The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction 显示文摘	Laeis P Puchler K Kirch W	2001	J Hypertens2001，19，1：	1
12	Rapid recovery of night blindness due to obesity surgery after vitamin A repletion therapy显示文摘	SPITS Y DE LAEY J J LEROY B P	2004	Br J Ophthalmol2004，88，4：	1
13	Blood pressure and endocrine effects of single doses CS-866,a novel angiotensin Ⅱ antagonist,in sahrestrlcted hypertensive patients显示文摘	Puchler K Nussberger J Laeis P	1997	J Hypertens1997，15，122：	1
14	The effect of an magnesium hydroxide) on the pharmacokinetics and safety of the oral angiotensin Ⅱ antagonist CS-866 in healthy male subjects 显示文摘	Kawaratani T Laeis P Puchler K	1999	J Hypertens1999，17，3：	1
15	Clinical efficacy of olmesartan medoxomil显示文摘	BrunnerHR Laeis P	2003	J Hypertens2003，21，2：	1
16	Olmesartan medoxomil:Influence of age,renal and hepatic function on the pharmacokinetics of Olmesartan medoxomil显示文摘	Von Bergmann K Laeis P Puchler K	2001	J Hypertens2001，19，1：	1
17	The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction显示文摘	Laeis P Puchler K Kiech W	2001	J Hypertens2001，19，：	1
18	Blood pressure and endocrine effects of single doses of CS-866, a novel angiotensin Ⅱ antagonist, in salt-restricted hypertensive patients显示文摘	PUCHLER K NUSSBERGER J LAEIS P	1997	J Hypertens1997，15，122：	1
19	Blood pressure response, but not adverse event incidence, correlates with dose of angiotension Ⅱ antagonist显示文摘	Puchler K Laeis P Stumpe KO	2001	J Hypertens2001，19，1：	1
20	Olmesartan medoxomil: influence of age, renal and hepatic function on the pharmacokinetics of olmesartan medoxomil 显示文摘	yon BERGMANN K LAEIS P PUCHLER K	2001	J Hypertens Suppl2001，191，：	1

返回顶部每页显示：

共3页首页上一页第1页下一页末页 /3 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示